PDCD1 and head and neck squamous cell carcinoma: Recently, a CheckMate 358 trial demonstrated that nivolumab induced pathological regression in HPV-positive and HPV-negative HNSCC (Ferris et al., 2021), and these results will provide a reference for investigating the addition of anti-PD-1 to adjuvant therapy in patients with locally advanced disease.